e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cystic fibrosis lung disease: what do we measure? What do we know?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Role of endothelin-1 in endothelial dysfunction in cystic fibrosis
C. Maurey, P. Henno, C. Delclaux, P. Bonnette, D. Israel-Biet, M. Levy (Paris, Suresnes, France)
Source:
Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Session:
Cystic fibrosis lung disease: what do we measure? What do we know?
Session type:
Electronic Poster Discussion
Number:
340
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Maurey, P. Henno, C. Delclaux, P. Bonnette, D. Israel-Biet, M. Levy (Paris, Suresnes, France). Role of endothelin-1 in endothelial dysfunction in cystic fibrosis. Eur Respir J 2007; 30: Suppl. 51, 340
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Endothelial dysfunction in cystic fibrosis: imbalance NOS/arginase?
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007
PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappa B and endothelin-1
Source: Eur Respir J 2009; 34: 1329-1337
Year: 2009
Role of endothelin in lung fibrosis
Source: Eur Respir Rev 2008; 17: 145-150
Year: 2008
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Imbalance between circulating endothelial cells and endothelial progenitors in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021
Year: 2021
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
Primary pulmonary hypertension and endothelial dysfunction
Source: Eur Respir J 2003; 22: Suppl. 45, 583s
Year: 2003
Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?
Source: Eur Respir J, 56 (4) 2003167; 10.1183/13993003.03167-2020
Year: 2020
Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 745s
Year: 2006
Arterial stiffness and endothelial dysfunction in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Thyroid hormone inhibits pulmonary fibrosis through enhancement of mitochondrial function in alveolar epithelial cells
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Premature vascular ageing in cystic fibrosis
Source: Eur Respir J 2009; 34: 1217-1218
Year: 2009
Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients
Source: Eur Respir J 2010; 36: 682-683
Year: 2010
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Impairment of membranous and vascular components of pulmonary diffusion and plasma endothelin-1 in patients with liver cirrhosis with and without COPD
Source: Annual Congress 2011 - COPD diagnosis
Year: 2011
LSC - 2021 - Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept